瑞达布韦

{{Infobox drug
| drug_name =
| IUPAC_name = 5-(3,3-Dimethylbut-1-yn-1-yl)-3-{(1R)-N-[(1s,4s)-4-hydroxy-4-({[(3S)-oxolan-3-yl]oxy}methyl)cyclohexyl]-4-methylcyclohex-3-ene-1-carboxamido}thiophene-2-carboxylic acid
| image = Radalbuvir.svg
| width = 250
| alt =
| caption =

| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US = Investigational New Drug
| legal_status =
| routes_of_administration =

| bioavailability =
| protein_bound =
| metabolism =
| onset =
| elimination_half-life =
| excretion =

| ATCvet =
| ATC_prefix =
| ATC_suffix =
| CAS_number = 1314795-11-3
| UNII_Ref =
| UNII = 273K4V0SPC
| PubChem = 53259022
| ChemSpiderID = 31140180
| ChEBI_Ref =
| ChEBI =
| DrugBank =
| synonyms = GS-9669

| chemical_formula =
| C=30 | H=41 | N=1 | O=6 | S=1
| SMILES = CC1=CCC@@HC(=O)N([C@H]2CCC@(O)CO[C@@H]3COCC3)c4c(sc(c4)C#CC(C)(C)C)C(=O)O
| StdInChI = 1S/C30H41NO6S/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35H,6-10,12,14-16,18-19H2,1-4H3,(H,33,34)/t21-,22-,23-,30+/m0/s1
| StdInChIKey = MUICUPWICXUNRS-GDCCIXDYSA-N
}}

瑞达布韦（INN：radalbuvir，开发代号：GS-9669）是吉利德科学公司开发的一种用于治疗丙型肝炎病毒（HCV）感染的实验性抗病毒药物。瑞达布韦可充当NS5B抑制剂。该药物目前正处于临床试验阶段。它针对NS5B聚合酶。

参考资料